Immunity to Hepatitis B is Undetectable in the Majority of Adolescents and Young Adults Seeking Outpatient Medication Treatment for Opioid Use Disorder.

Authors:

Samuel W Stull Erin R McKnight Steven C Matson Andrea E Bonny

J Addict Med 2020 12;14(6):e359-e361

Department of Biobehavioral Health, The Pennsylvania State University, PA (SWS); Division of Adolescent Medicine, Nationwide Children's Hospital, Columbus, OH (SWS, ERM, SCM, AEB); Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH (ERM, SCM, AEB); Center for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH (AEB).

Objective: To assess prevalence and predictors of hepatitis B immune status among adolescents and young adults (AYA) seeking outpatient medication treatment for opioid use disorder (MOUD).

Study Design: A retrospective medical chart review was conducted of AYA seeking MOUD between January 1, 2013 through December 31, 2015. Inclusion criteria included: diagnosis of opioid use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; received hepatitis serologic testing; and no evidence of prior or current hepatitis B infection. Hepatitis B immunization initiation was defined as a record of at least 1 hepatitis B vaccination; while receipt of at least 3 vaccinations indicated immunization completion. The presence of hepatitis B surface antibody (anti-HBs) was the primary outcome measure.

Results: Of the 193 patients that met eligibility criteria, the presence of anti-HBs was evident in 62 (32.1%). Hepatitis B immunization initiation and completion before presenting for MOUD was documented in 102 (52.9%) and 84 (43.5%). In multivariable logistic regression modeling, hepatitis B immunization initiation after infancy was associated with increased odds of having protective anti-HBs relative to immunization series initiation in infancy (OR 8.96, 95% CI 1.57-51.05). Completion of hepatitis B immunization series after infancy as compared to completion in infancy also increased the odds of protective anti-HBs (OR, 6.68, 95% CI 2.10-21.24).

Conclusions: Rates of immunity to hepatitis B were low in AYA seeking MOUD. It is important to immunize patients seeking MOUD for hepatitis B and follow up with checks for seroconversion.

Download full-text PDF	Source
http://dx.doi.org/10.1097/ADM.0000000000000689	DOI Listing

December 2020

Publication Analysis

Keyword Occurance

Similar Publications

Autoimmune hepatitis triggered by COVID-19 vaccination: correspondence.

Authors:

Rujittika Mungmunpuntipantip Viroj Wiwanitkit

Clin J Gastroenterol 2022 Aug 10. Epub 2022 Aug 10.

Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria.

View Article and Full-Text PDF

August 2022

Similar Publications

Reply to the Letter to Editor regarding "Autoimmune hepatitis with history of HCV treatment triggered by COVID‑19 vaccination: case report and literature review".

Authors:

Naoyuki Hasegawa Ryota Matsuoka Naoki Ishikawa Masato Endo Masahiko Terasaki Emiko Seo Kiichiro Tsuchiya

Clin J Gastroenterol 2022 Aug 10. Epub 2022 Aug 10.

Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan.

View Article and Full-Text PDF

August 2022

Similar Publications

Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS1 antigen.

Authors:

Ana-Maria Pantazica Mihaela-Olivia Dobrica Catalin Lazar Cristina Scurtu Catalin Tucureanu Iuliana Caras Irina Ionescu Adriana Costache Adrian Onu Jihong Liu Clarke Crina Stavaru Norica Branza-Nichita

Front Immunol 2022 22;13:941243. Epub 2022 Jul 22.

Department of Viral Glycoproteins, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania.

Despite the availability of improved antiviral therapies, infection with Hepatitis B virus (HBV) remains a3 significant health issue, as a curable treatment is yet to be discovered. Current HBV vaccines relaying on the efficient expression of the small (S) envelope protein in yeast and the implementation of mass vaccination programs have clearly contributed to containment of the disease. However, the lack of an efficient immune response in up to 10% of vaccinated adults, the controversies regarding the seroprotection persistence in vaccine responders and the emergence of vaccine escape virus mutations urge for the development of better HBV immunogens. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

Hepatitis B vaccination coverage amongst healthcare workers in a tertiary academic hospital in Gauteng province, South Africa.

Authors:

Lufuno L Razwiedani Ntlogeleng M Mogale Muthuhadini P B Mawela

S Afr J Infect Dis 2022 27;37(1):393. Epub 2022 Jul 27.

Department of Pediatrics, Faculty of Health Sciences, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa.

Background: Chronic infection with hepatitis B virus (HBV) is a major public health concern in South Africa. Hepatitis B virus is a highly infectious blood-borne virus causing liver disease. Healthcare workers (HCWs) are at high risk of occupational exposure. Read More

View Article and Full-Text PDF

July 2022

Similar Publications

Antibody response to an accelerated course of Hepatitis B vaccination.

Authors:

P C S Lian B Morrish

Occup Med (Lond) 2022 Aug 6. Epub 2022 Aug 6.

Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

Background: There are several courses with different dosing intervals for Hepatitis B vaccination. This independent study is looking at the antibody response after three doses of the accelerated course.

Aims: The primary aim of the study was to examine data available at an Occupational Health Service for the antibody response to one or if nonresponsive, two accelerated Hepatitis B courses. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

}

Search Our Scientific Publications & Authors